Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2002-04-18
2003-09-16
Ketter, James (Department: 1636)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Reexamination Certificate
active
06620913
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to discovery of a novel Hantavirus. In particular, the present invention relates to nucleic acids of the novel Hantavirus and to nucleic acid reagents and antibodies for use in methods of detection and prevention of infection by the new virus.
BACKGROUND ART
Recently, an outbreak of an unknown disease presenting with the abrupt onset of fever, myalgia, headache, cough and finally respiratory failure occurred in the Four Corners Region of the United States. The disease has been clinically termed ARDS (unexplained Adult Respiratory Distress Syndrome). Of the 12 human cases that have been reported, 75% of these patients have died. The outbreak appears to be confined primarily to the Four Corners Region of New Mexico, Arizona and Colorado.
The high mortality associated with ARDS and the unknown etiology of the pathogen created an urgent need to isolate and identify the pathogen and to provide reliable methods for diagnosis, treatment and prevention of the disease. The present invention satisfied that need by identifying a previously unreported strain of Hantavirus as the causative agent of the ARDS outbreak. The present invention also provides methods to diagnose and prevent infection.
SUMMARY OF THE INVENTION
The present invention provides the discovery and isolation of a new virus. This virus is the etiologic agent responsible for the outbreak of the Adult Respiratory Distress Syndrome (ARDS) in the Four Corners Region of the United States. Based upon genetic characteristics, this new virus should be classified in the Hantavirus family.
The present invention also provides isolated nucleic acids and nucleic acid reagents which can be utilized to diagnose and prevent infection of the new virus. Purified polypeptides encoded by the nucleic acids are also provided. These polypeptides can be utilized in methods of diagnosis or as vaccine components for prevention of infection.
Vectors are also provided which comprise the nucleic acids of the present invention. The vectors can be utilized in host expression systems to produce antigenic peptide reagents for diagnostic and prophylactic applications.
The present invention also provides purified antibodies selectively reactive with the new virus of the invention. These antibodies can be used in various diagnostic methods or as a therapeutic.
REFERENCES:
Sommer and Tautz, “Minimal homology requirements for PCR primers,” Nucleic Acids Research 17(16):6749 (1989).
Sequence Comparison # 6 pp. 24-25.
Antic et al., “Comparison of the deduced gene products of the L, M, and S genome segments of hantaviruses,” Virus Res. 24:35-46 (1992).
CDC, “Outbreak of acute illness-Southwestern United States, 1993” Morbidity and Mortality Weekly Report 42:421-424 (Jun. 11, 1993).
CDC, “Outbreak of acute illness-Southwestern United States, 1993” Morbidity and Mortality Weekly Report 42:477-479 (Jun. 25, 1993).
CDC, “Outbreak of acute illness-Southwestern United States, 1993” Morbidity and Mortality Weekly Report 42:495-496 (Jul. 2, 1993).
CDC, “Outbreak of acute illness-Southwestern United States, 1993” Morbidity and Mortality Weekly Report 42:570-571 (Jul. 30, 1993).
CDC, “Outbreak of acute illness-Southwestern United States, 1993” Morbidity and Mortality Weekly Report 42:612-614 (Aug. 13, 1993).
Elliott et al., “Nucleotide Sequence and Expression of the Small (S) RNA Segment of Maguari Bunyavirus,” Virology, 171:516-524 (1989).
Kallio-Kokko et al., “Puumala virus Antibody and Immunoglobulin G Avidity Assays Based on a Recombinant Nucleocapsid Antigen,” Journal of Clinical Microbiology 31:368-372 (Mar., 1993).
Lundkvist et al., “Immunoglobulin G Subclass Responses against the Structural Components of Puumala Virus,” Journal of Clinical Microbiology 31:368-372 (Feb. 1993).
Yoo, et al., “Genomic comparison among members of Hantavirus group,” In The Biology of Negative Strand Virus, Mahy & Kolakofsky (Eds.), Elsvier Science Publishers BV (1987).
CDC, “Update: Outbreak of acute illness—Southwestern United States, 1993,”Morbidity and Mortality Weekly Report42:441-443 (Jun. 18, 1993).
Schmaljohn and Patterson in Fundamental Virology, 2nd Ed., “Bunyaviridae and Their Replication” pp. 545-564 (1991).
Plummer et al. People Weekly, 30-33 (Jun. 21, 1993).
Ksiazek Thomas G.
Nichol Stuart T.
Rollin Pierre E.
Spiropoulou Christina F.
Katcheves Konstantina
Ketter James
Needle & Rosenberg P.C.
The United States of America as represented by the Department of
LandOfFree
Polypeptides of a novel hantavirus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypeptides of a novel hantavirus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptides of a novel hantavirus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3021501